앱토럼 그룹 (NIKI) 주가 전망: 목표주가, 배당, 최신 뉴스

Niki BioSolutions, Inc. , through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.

Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.

The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections.

The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.

Niki BioSolutions, Inc.는 자회사를 통해 운영되는 임상 단계 바이오제약 회사로, 종양학 및 감염병 치료제를 발굴·개발·상품화하는 데 주력하고 있습니다.

파이프라인으로는 기존 약물 재목적화 후보인 SACT-1이 신경모세포종 및 기타 암종 치료를 위한 Phase 1 임상시험 진행 중이며, 소분자 재목적화 후보인 ALS-4는 황색포도상구균(staphylococcus aureus), 결핵균(mycobacterium tuberculosis), 녹농균(pseudomonas aeruginosa) 등 세균 감염 치료를 위한 Phase 1 임상시험에 있습니다. 또한 SACT-COV19는 코로나19 치료를 위한 전임상 단계에 있고, SACT-2·SACT-3, ALS-1(황색포도상구균·MRSA 치료 전임상) 및 ALS-2/3(그람 양성(gram+ve) 세균 감염 전임상) 등도 개발 중입니다.

회사는 2010년에 설립되었고 본사는 뉴저지주 프린스턴에 위치해 있으며, 2026년 7월에 이전 명칭 Aptorum Group Limited에서 Niki BioSolutions, Inc.로 사명을 변경했습니다. 현재 Jurchen Investment Corporation의 자회사로 운영되고 있습니다.

• 주소: 116 Village Boulevard, Suite 200, Princeton, NJ 08540, United States

• 전화번호: 609 951 2222

• 웹사이트: https://www.aptorumgroup.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 1